Jeffrey S Heier Selected Research

aflibercept

5/2022	Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
1/2022	INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial.
1/2022	MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
9/2021	Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
5/2021	Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial.
1/2021	Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
1/2020	Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.
12/2019	Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
2/2017	Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials.
11/2016	Vascular endothelial growth factor and diabetic macular edema.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey S Heier Research Topics

Disease

43	Macular Degeneration (Age-Related Maculopathy) 05/2022 - 11/2005
24	Macular Edema 01/2022 - 04/2005
10	Inflammation (Inflammations) 01/2022 - 04/2006
10	Choroidal Neovascularization 05/2021 - 04/2006
10	Retinal Vein Occlusion 01/2020 - 04/2005
7	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2022 - 12/2012
7	Endophthalmitis (Ophthalmia) 01/2021 - 10/2006
5	Geographic Atrophy 01/2020 - 11/2008
4	Retinal Vasculitis 05/2022 - 11/2018
3	Retinal Perforations 01/2019 - 11/2013
3	Retinal Detachment (Retinal Detachments) 06/2016 - 02/2010
3	Cicatrix (Scar) 02/2010 - 11/2008
2	Vascular Diseases (Vascular Disease) 01/2021 - 01/2020
2	Cataract (Cataracts) 11/2018 - 08/2010
2	Vision Disorders (Hemeralopia) 10/2018 - 11/2006
2	Vitreous Detachment (Posterior Vitreous Detachment) 01/2017 - 11/2013
2	Edema (Dropsy) 11/2016 - 01/2014
2	Proliferative Vitreoretinopathy 06/2016 - 02/2010
2	Stroke (Strokes) 03/2015 - 11/2006
2	Uveitis 10/2006 - 10/2006
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2021
1	Vasculitis (Vasculitides) 11/2018
1	Plexiform Neurofibroma 01/2017
1	vitreous floaters 01/2017
1	Fever (Fevers) 01/2017
1	Microaneurysm 11/2016
1	Neoplasms (Cancer) 08/2016
1	Infections 01/2016
1	Myopia 01/2016
1	Pneumonia (Pneumonitis) 03/2015
1	Pain (Aches) 10/2014
1	Vitreous Hemorrhage 07/2014
1	Glaucoma 08/2010
1	Lens Subluxation 08/2010
1	Wounds and Injuries (Trauma) 06/2010
1	Atrophy 06/2009
1	Fibrosis (Cirrhosis) 06/2009
1	Pathologic Processes 06/2009

Drug/Important Bio-Agent (IBA)

28	afliberceptIBA 05/2022 - 06/2011
25	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 04/2006
23	Ranibizumab (Lucentis)FDA Link 11/2016 - 04/2006
15	Retinaldehyde (Retinal)IBA 05/2022 - 11/2005
7	Bevacizumab (Avastin)FDA Link 11/2016 - 11/2008
5	salicylhydroxamic acid (SHAM)IBA 05/2021 - 10/2006
4	Fluorescein (Funduscein)FDA LinkGeneric 05/2021 - 04/2012
3	brolucizumabIBA 05/2022 - 01/2021
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2016
3	Proteins (Proteins, Gene)FDA Link 01/2017 - 04/2013
3	Biological ProductsIBA 03/2015 - 10/2006
3	Verteporfin (Visudyne)FDA Link 01/2009 - 10/2006
2	SteroidsIBA 01/2017 - 10/2014
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2009 - 11/2006
2	Monoclonal AntibodiesIBA 10/2006 - 10/2006
1	Neurofibromin 2 (Merlin)IBA 01/2022
1	faricimabIBA 01/2022
1	Endothelial Growth FactorsIBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Platelet-Derived Growth FactorIBA 01/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021
1	AngiopoietinsIBA 01/2021
1	Complement C3 (C3 Complement)IBA 01/2020
1	KH902 fusion proteinIBA 01/2020
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2020
1	pegcetacoplanIBA 01/2020
1	Vancomycin FDA LinkGeneric 11/2018
1	SolutionsIBA 11/2018
1	emixustatIBA 10/2018
1	AZD 6244IBA 01/2017
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2016
1	Mitogen-Activated Protein KinasesIBA 08/2016
1	binimetinibIBA 08/2016
1	AKB-9778IBA 03/2015
1	Class 3 Receptor-Like Protein Tyrosine PhosphatasesIBA 03/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2014
1	Genetic Markers (Genetic Marker)IBA 09/2013
1	Designed Ankyrin Repeat ProteinsIBA 04/2013
1	MP0112IBA 04/2013
1	tetrachloroisophthalonitrile (Bravo)IBA 04/2012
1	Ciliary Neurotrophic Factor (CNTF)IBA 04/2011
1	Explosive Agents (Explosives)IBA 06/2010
1	Integrin alpha5beta1IBA 02/2010
1	Bromodeoxyuridine (BrdU)IBA 02/2010
1	JSM6427IBA 02/2010
1	KetorolacIBA 10/2009
1	ProstaglandinsIBA 10/2009

Therapy/Procedure

11	Injections 09/2021 - 04/2006
11	Lasers (Laser) 02/2017 - 04/2005
9	Therapeutics 01/2022 - 06/2009
6	Light Coagulation 02/2017 - 01/2014
6	Intravitreal Injections 10/2014 - 04/2006
4	Vitrectomy 01/2019 - 08/2010
3	Photochemotherapy (Photodynamic Therapy) 01/2009 - 10/2006
2	Intraocular Injections 01/2017 - 06/2010
2	Traction 01/2014 - 11/2013
2	Telescopes 11/2008 - 11/2006
1	Solid-State Lasers 01/2017
1	Aftercare (After-Treatment) 07/2014
1	Endoscopes 05/2014
1	Cataract Extraction 08/2010
1	Trabeculectomy (Trabeculoplasty) 08/2010